Progesterone Induced Blocking Factor Expression Levels in Endometrial Cancer Cells.

Progesterone Induced Blocking Factor in Endometrial Cancer Clinical Trial

Official title:

Determining Levels of Expression of Progesterone-Induced Blocking Factor in Endometrial Cancer Cells.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02852954
• Other study ID #: 2016/405
• Status: Completed
• Phase: N/A
• First received: July 29, 2016
• Last updated: August 15, 2017
• Start date: August 2016
• Est. completion date: March 2017

Study information

• Verified date: August 2016
• Source: Kayseri Education and Research Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Immune system suppression effect of Progesterone Induced Blocking Factor(PIBF), it could be questionable whether tumor cells express PIBF for escape of immune system. There are some studies in the literature that evaluate PIBF expression of different malign cells (e.g. glioblastoma multiforme as a malign central nerve system, leukemia, astrocytoma as a primary brain tumor, lung cancer and chorionic carcinoma). According to previous studies PIBF has been used as an anti-tumor immune suppressor by tumor cells. There is no data about the PIBF expression of endometrial tumor cells. Therefore, the investigators aim to determine the PIBF expression levels in the endometrial cancer cells.

Description:

This retrospective controlled study will be conducted at both Obstetrics and Gynecology clinics and Pathology clinics of Kayseri Training and Research Hospital. This study will be conducted with the use of formalin fixed paraffin embedded tissue blocks immunohistochemically to determine the PIBF expression levels in the samples. There are three groups in this study; endometrial cancer, endometrial hyperplasia and normal endometrium and each of the groups contained 20 paraffin embedded blocks provided form the Pathology clinic of Kayseri Training and Research Hospital archives.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: March 2017
• Est. primary completion date: December 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 20 Years to 70 Years

Eligibility

Inclusion Criteria:

• diagnosed endometrial cancer

• diagnosed endometrial hyperplasia

Exclusion Criteria:

• diagnosed cancer except endometrial cancer

Related Conditions & MeSH terms

• Endometrial Neoplasms
• Progesterone Induced Blocking Factor in Endometrial Cancer

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Kayseri Education and Research Hospital

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Immunohistochemically Levels of PIBF in Endometrial Cancer Cells		3 months